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Summary
Background Anti-tumour necrosis factor (anti-TNF) therapies are the most widely used biologic therapies for treating immune-mediated diseases. Their efficacy is significantly reduced by the development of anti-drug antibodies which can lead to treatment failure and adverse reactions. The biological mechanisms underlying antibody development are unknown but the ability to identify subjects at higher risk would have significant clinical benefits.
Methods
The PANTS cohort consists of Crohn's disease patients recruited prior to first administration of anti-TNF, with serial measurements of anti-drug antibody titres. We performed a genomewide association study across 1240 individuals from this cohort to identify genetic variants associated with anti-drug antibody development.
Findings
The Human Leukocyte Antigen allele, HLA-DQA1*05, carried by approximately 40% of Europeans, significantly increased the rate of anti-drug antibody development (hazard ratio 
Introduction
Biological therapies, commonly known as biologics, are typically large and complex proteins manufactured in, or derived from, living sources. Biologics have transformed the management of immune-mediated diseases and in 2017 accounted for a global expenditure in excess of $100 billion. 1 However, repeated exposure stimulates the formation of anti-drug antibodies -the most frequently cited cause of treatment failure, hypersensitivity reactions, and treatment discontinuation. 2 The anti-tumour necrosis factor antibodies (anti-TNFs), infliximab and adalimumab, are the most commonly prescribed biologics for treating inflammatory bowel disease (IBD) 3 . The risk of development of anti-drug antibodies, referred to as immunogenicity, is higher for patients treated with infliximab (a murine-human chimeric monoclonal antibody) than adalimumab (a fully humanised monoclonal antibody). 2 Combination immunomodulator therapy reduces immunogenicity to both adalimumab and infliximab and for infliximab improves treatment outcomes. 4, 5 Despite these benefits, many patients are still treated with anti-TNF monotherapy because of concerns about the increased risk of adverse drug reactions, opportunistic infections, and malignancies associated with combination therapy. [6] [7] [8] [9] [10] Knowledge of the cellular and molecular mechanisms underpinning failure of immune tolerance to biologics is limited. Retrospective candidate gene studies have suggested variants in FCGR3A 11 and HLA-DRB1 12, 13 increase susceptibility to immunogenicity to anti-TNF therapy. However, these associations did not achieve genome-wide significance and are yet to be independently replicated.
Here we report the first genetic locus robustly associated with immunogenicity to anti-TNF therapies using data from the Personalising Anti-TNF Therapy in Crohn's disease (PANTS) study. adalimumab drug level) and total antibody ELISA assays (K9654 infliximab total anti-drug antibody and K9651 adalimumab total anti-drug antibody). Based on our own independent assay experiments, 14 we defined immunogenicity as an anti-drug antibody concentration ≥10 AU/mL, irrespective of drug concentration.
Genotyping, quality control and genotype imputation Genotyping of DNA from 1524 patients was undertaken using the Illumina CoreExome microarray, with genotype calls made using optiCall. 15 Pre-imputation quality control (QC) of samples and single nucleotide polymorphisms (SNPs) was performed as previously described. 16 We excluded individuals of non-European ancestry, one individual from related pairs (defined as a pi-hat>0.1875), and individuals with an outlying number of missing or heterozygous genotypes. Variants with a genotype call rate of <95% were also excluded.
SNP genotypes were imputed via the Sanger Imputation Service using the Haplotype Reference Consortium (HRC) panel. 17 Following imputation we ran additional variant and sample QC procedures (appendix methods).
HLA imputation was carried out using the HIBAG package 18 separates alleles which differ in nucleotide positions that determine amino acid sequences, whereas the lower, 2-digit resolution separates allele families. In addition, we obtained amino acid sequences for all the imputed HLA alleles, using the IPD-IMGT/HLA database. 19 Following the recommended best practices for HIBAG, 18 HLA-allele and amino acid calls with posterior probability <0.5 were set to missing for the given individual. HIBAG's imputation accuracy is very high in Europeans, above 94% across all HLA loci and above 99% for the HLA-DQA1 locus specifically. 20 Furthermore, we validated the imputation accuracy for HLA-DQA1*05 at 2D resolution using typed HLA data (appendix table S1).
Genome-wide association analyses
Cox proportional hazards regression was used to test genetic variants and for association with time to anti-drug antibody development, assuming an additive genetic effect. Patients who did not develop immunogenicity during the study were censored at the point of last observation. The association analyses were performed using a likelihood ratio test with sex, drug type (infliximab or adalimumab), immunomodulator use, and the first principal component as covariates (appendix table S2), with the SurvivalGWAS_SV software. 21 Kaplan-Meier estimators were produced using the Lifelines package 22 for Python.
The Akaike information criterion (AIC), calculated using the 'survival' R package, 23 was used for model comparison across non-nested models; this estimates the goodness of fit while penalising for the number of parameters to prevent overfitting. The fixed effects Q statistic, calculated using the 'metafor' R package, 24 was used to perform tests of heterogeneity of effect; this test is an extension of Cochran's Q-test and examines whether the observed effect size variability is larger than expected by chance.
Replication cohort
We assembled an independent cohort to replicate significant findings from the discovery cohort. This comprised 107 Crohn's disease, 64 ulcerative colitis, and 7 IBD typeunclassified patients, all with cross-sectional drug and antibody levels measured as part of routine clinical practice at the Exeter laboratory. The samples were genotyped using either the Illumina CoreExome array (N=164) 16 or the Affymetrix 500k array (N=14). 25 We repeated the same quality control procedures and imputation (genotype and HLA) undertaken on the PANTS discovery cohort. We applied the same statistical model used for the discovery analysis, with IBD disease type as an additional covariate.
Results
Of the 1610 patients recruited to the PANTS study, 1524 were genotyped, and 1323 of these passed genetic QC, ancestry, and relatedness analyses. Drug and antibody level data were available for 1240 of these patients (appendix figure S2, appendix The effect of HLA-DQA1*05 across drug and treatment regimes While immunogenicity rates were lower with adalimumab versus infliximab treated patients, the effect of HLA-DQA1*05 carriage was the same for the two therapies (P het =0.91) (figure 4). We also found no evidence for heterogeneity of the HLA-DQA1*05 effect on immunogenicity (P het =0.23) between patients treated with the infliximab originator, Remicade (Merck Sharp & Dohme Corp), and its biosimilar CT-P13 (Celltrion, South Korea; branded as Remsima, Napp UK, and Inflectra, Pfizer, USA) (appendix figure S7). These findings support the previously reported similar antigenic profile for infliximab originator and CT-P13. 28 Likewise, the effect of HLA-DQA1*05 carriage on immunogenicity was consistent for individuals on mono-versus combination therapy with immunomodulators (P het =0.14).
9 Immunogenicity is more common in patients treated with infliximab than adalimumab.
Arguably then, all patients treated with infliximab, as well as HLA-DQA1*05 carriers treated with adalimumab, should also be treated with an immunomodulator. Conversely, patients who do not carry HLA-DQA1*05, in particular those at high risk of opportunistic infections or those with a history of adverse drug reactions to thiopurines and/or methotrexate, could be spared the additional risks of combination therapy and treated with adalimumab monotherapy.
The shared genetic association between HLA-DQA1*05 and immunogenicity to infliximab and adalimumab may explain the widely reported diminishing returns of switching between anti-TNF therapies at loss of response. 29, 30 If the HLA-DQA1*05 immunogenic effect extends to other therapeutic antibodies, then subjects who are HLA-DQA1*05 carriers may be candidates for non-antibody modality therapies such as small molecule drugs.
How variation in the HLA predisposes to immunogenicity is poorly elucidated. The HLA class II gene HLA-DQA1 is expressed by antigen presenting cells and encodes the alpha chain of the HLA-DQ heterodimer that forms part of the antigen binding site where epitopes are presented to T helper cells. Previous studies have shown that it is possible to map and eliminate potential immunogenic T cell epitopes with the aim of producing a safer, more durable biologic. [31] [32] [33] However, caution needs to be exercised to ensure protein sequence modifications designed to reduce the risk of immunogenicity to patients carrying HLA-DQA1*05 do not put a different group of patients at risk.
We acknowledge several important limitations. Firstly, multiple assays are available to detect anti-drug antibodies and there is no universally accepted, validated threshold to diagnose immunogenicity. Detecting anti-drug antibodies in the presence of drug is difficult and consequently we may have underestimated the proportion of patients with immunogenicity.
We deliberately chose a drug tolerant assay in order to mitigate this risk and to minimise the number of false negative patients assigned to the control group, and confirmed that the HLA-DQA1*05 association is robust to the choice of threshold for immunogenicity (appendix figure S5 ). Secondly, we may have underestimated the contribution of HLA-DQA1*05 to immunogenicity because of the short duration of follow-up in patients who did not continue in the study beyond the first year. Thirdly, because we designed a schedule of visits to minimise patients' inconvenience, the number of assessments was less for those treated with adalimumab than infliximab. 38 , further studies are required to assess the contribution of HLA-DQA1*05 to immunogenicity across populations. Whether HLA-DQA1*05 is also associated with immunogenicity to other biologic drugs also needs to be determined.
In conclusion, immunogenicity is a major concern for patients, regulatory authorities, and the 
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